Marktanalyse - Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2016

Global Markets Direct
12.2016
492 Seiten

 
Typ:
Marktanalyse
Verfüg­barkeit:
verfügbar
Regionen/­Länder:
  • Europa
  • Asien / Pazifik
  • Mittlerer Osten / Afrika
  • Nordamerika / USA
  • Australien
  • Mittel- / Südamerika
Sprache:
Englisch

Bitte wählen Sie ein Lieferformat und klicken Sie unten auf einen Bestellbutton:

PDF-Datei per E-Mail, Single User Price, versandkostenfrei
PDF-Datei per E-Mail, Site License Price**, versandkostenfrei
PDF-Datei per E-Mail, Enterprisewide Price (Global Site License)***, versandkostenfrei


Hinweise: **The report can be shared by users within one office (one geographical location) ***Across Geographical locations (by the purchasing company only)

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Review, H2 2016


Summary


Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Bile Duct Cancer (Cholangiocarcinoma) — Pipeline Review, H2 2016, provides an overview of the Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline landscape.

Bile duct cancer or cholangiocarcinoma are tumors that occur in the bile duct. Symptoms include discomfort in the tummy area (abdomen), loss of appetite, high temperatures (fevers) and weight loss. Treatment includes chemotherapy and radiation therapy.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Bile Duct Cancer (Cholangiocarcinoma) — Pipeline Review, H2 2016, provides comprehensive information on the therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Bile Duct Cancer (Cholangiocarcinoma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 49, 18, 10 and 3 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 1, 1 and 4 molecules, respectively.Bile Duct Cancer (Cholangiocarcinoma).

Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.


Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Bile Duct Cancer (Cholangiocarcinoma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Bile Duct Cancer (Cholangiocarcinoma) (Oncology)


Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Bile Duct Cancer (Cholangiocarcinoma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Bile Duct Cancer (Cholangiocarcinoma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents

Table of Contents 2

Introduction 6

Bile Duct Cancer (Cholangiocarcinoma) Overview 7

Therapeutics Development 8

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Development by Companies 10

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics under Investigation by Universities/Institutes 14

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline Products Glance 15

Bile Duct Cancer (Cholangiocarcinoma) - Products under Development by Companies 18

Bile Duct Cancer (Cholangiocarcinoma) - Products under Investigation by Universities/Institutes 23

Bile Duct Cancer (Cholangiocarcinoma) - Companies Involved in Therapeutics Development 24

Bile Duct Cancer (Cholangiocarcinoma) - Therapeutics Assessment 87

Drug Profiles 101

Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects 464

Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products 467

Bile Duct Cancer (Cholangiocarcinoma) - Product Development Milestones 468

Appendix 481





List of Tables

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2016 18

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H2 2016 19

Number of Products under Development by Companies, H2 2016 20

Number of Products under Development by Companies, H2 2016 (Contd..1) 21

Number of Products under Development by Companies, H2 2016 (Contd..2) 22

Number of Products under Development by Companies, H2 2016 (Contd..3) 23

Number of Products under Investigation by Universities/Institutes, H2 2016 24

Comparative Analysis by Late Stage Development, H2 2016 25

Comparative Analysis by Clinical Stage Development, H2 2016 26

Comparative Analysis by Early Stage Development, H2 2016 27

Products under Development by Companies, H2 2016 28

Products under Development by Companies, H2 2016 (Contd..1) 29

Products under Development by Companies, H2 2016 (Contd..2) 30

Products under Development by Companies, H2 2016 (Contd..3) 31

Products under Development by Companies, H2 2016 (Contd..4) 32

Products under Investigation by Universities/Institutes, H2 2016 33

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by 4SC AG, H2 2016 34

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Adgero Biopharmaceuticals Inc, H2 2016 35

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Agios Pharmaceuticals Inc, H2 2016 36

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ariad Pharmaceuticals Inc, H2 2016 37

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by ArQule Inc, H2 2016 38

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Array BioPharma Inc, H2 2016 39

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Arrien Pharmaceuticals LLC, H2 2016 40

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Aslan Pharmaceuticals Pte Ltd, H2 2016 41

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bavarian Nordic A/S, H2 2016 42

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bayer AG, H2 2016 43

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by BeiGene Ltd, H2 2016 44

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Blueprint Medicines Corp, H2 2016 45

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boehringer Ingelheim GmbH, H2 2016 46

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Boston Biomedical Inc, H2 2016 47

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Bristol-Myers Squibb Company, H2 2016 48

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Celgene Corp, H2 2016 49

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by CellAct Pharma GmbH, H2 2016 50

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellceutix Corp, H2 2016 51

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cellular Biomedicine Group Inc, H2 2016 52

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Concordia International Corp, H2 2016 53

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Cornerstone Pharmaceuticals Inc, H2 2016 54

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Daiichi Sankyo Company Ltd, H2 2016 55

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Delcath Systems Inc, H2 2016 56

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eisai Co Ltd, H2 2016 57

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Eli Lilly and Company, H2 2016 58

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Exelixis Inc, H2 2016 59

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by F. Hoffmann-La Roche Ltd, H2 2016 60

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by H3 Biomedicine Inc, H2 2016 61

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Halozyme Therapeutics Inc, H2 2016 62

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Hutchison MediPharma Ltd, H2 2016 63

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Incyte Corp, H2 2016 64

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Innopharmax Inc, H2 2016 65

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by INSYS Therapeutics Inc, H2 2016 66

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Johnson & Johnson, H2 2016 67

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Komipharm International Co Ltd, H2 2016 68

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Loxo Oncology, Inc., H2 2016 69

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Mebiopharm Co Ltd, H2 2016 70

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by MedImmune LLC, H2 2016 71

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Merck & Co Inc, H2 2016 72

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NanoCarrier Co Ltd, H2 2016 73

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NormOxys Inc, H2 2016 74

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Novartis AG, H2 2016 75

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by NuCana BioMed Ltd, H2 2016 76

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Oasmia Pharmaceutical AB, H2 2016 77

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by OncoTherapy Science Inc, H2 2016 78

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Ono Pharmaceutical Co Ltd, H2 2016 79

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Panacea Pharmaceuticals Inc, H2 2016 80

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by PCI Biotech Holding ASA, H2 2016 81

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pfizer Inc, H2 2016 82

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Pharma Mar SA, H2 2016 83

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Provecs Medical GmbH, H2 2016 84

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Puma Biotechnology Inc, H2 2016 85

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by RedHill Biopharma Ltd, H2 2016 86

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sanofi, H2 2016 87

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Senhwa Biosciences Inc, H2 2016 88

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Shanghai Pharmaceutical Co Ltd, H2 2016 89

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Sun Pharma Advanced Research Company Ltd, H2 2016 90

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by SynCore Biotechnology Co Ltd, H2 2016 91

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by SyntheX Inc, H2 2016 92

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Taiwan Liposome Company Ltd, H2 2016 93

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by tella Inc, H2 2016 94

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by Threshold Pharmaceuticals Inc, H2 2016 95

Bile Duct Cancer (Cholangiocarcinoma) - Pipeline by VasGene Therapeutics Inc, H2 2016 96

Assessment by Monotherapy Products, H2 2016 97

Assessment by Combination Products, H2 2016 98

Number of Products by Stage and Target, H2 2016 100

Number of Products by Stage and Mechanism of Action, H2 2016 104

Number of Products by Stage and Route of Administration, H2 2016 108

Number of Products by Stage and Molecule Type, H2 2016 110

Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects, H2 2016 474

Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..1), H2 2016 475

Bile Duct Cancer (Cholangiocarcinoma) - Dormant Projects (Contd..2), H2 2016 476

Bile Duct Cancer (Cholangiocarcinoma) - Discontinued Products, H2 2016 477





List of Figures

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma), H2 2016 18

Number of Products under Development for Bile Duct Cancer (Cholangiocarcinoma) - Comparative Analysis, H2 2016 19

Number of Products under Development by Companies, H2 2016 20

Number of Products under Investigation by Universities/Institutes, H2 2016 24

Comparative Analysis by Clinical Stage Development, H2 2016 26

Comparative Analysis by Early Stage Products, H2 2016 27

Assessment by Monotherapy Products, H2 2016 97

Number of Products by Top 10 Targets, H2 2016 99

Number of Products by Stage and Top 10 Targets, H2 2016 99

Number of Products by Top 10 Mechanism of Actions, H2 2016 103

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 103

Number of Products by Routes of Administration, H2 2016 107

Number of Products by Stage and Routes of Administration, H2 2016 107

Number of Products by Molecule Types, H2 2016 109

Number of Products by Stage and Molecule Types, H2 2016 109

* Alle Preise sind netto ausgewiesen. In Abhängigkeit von Ihrer Rechnungsanschrift ist hierauf noch USt. zu entrichten (Deutschland z.Z. 19%). Unser Angebot richtet sich ausschließlich an Unternehmen, Gewerbetreibende und Freiberufler.

 

Über marktforschung.de

Branchenwissen an zentraler Stelle bündeln und abrufbar machen – das ist das Hauptanliegen von marktforschung.de. Unser breites Informationsangebot rund um die Marktforschung richtet sich sowohl an Marktforschungsinstitute, Felddienstleister, Panelbetreiber und Herausgeber von Studien, Marktdaten sowie Marktanalysen als auch an deren Kunden aus Industrie, Handel und Dienstleistungsgewerbe.

facebook twitter google plus